Intech Investment Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 103.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,826 shares of the biopharmaceutical company's stock after acquiring an additional 33,431 shares during the period. Intech Investment Management LLC owned about 0.06% of Catalyst Pharmaceuticals worth $1,374,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $27,000. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Larson Financial Group LLC boosted its stake in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $65,000. Finally, KBC Group NV grew its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 1,542 shares during the last quarter. Institutional investors own 79.22% of the company's stock.
Insider Activity
In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Bank of America reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average price target of $32.29.
Read Our Latest Report on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Stock Performance
CPRX stock traded down $0.57 on Wednesday, reaching $25.15. The company's stock had a trading volume of 1,476,911 shares, compared to its average volume of 1,066,729. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $26.16. The firm has a market cap of $3.05 billion, a PE ratio of 21.31, a PEG ratio of 3.31 and a beta of 0.84. The business has a fifty day simple moving average of $22.53 and a two-hundred day simple moving average of $21.72.
Catalyst Pharmaceuticals Company Profile
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Articles
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
